Nasdaq · CIK 0001799191
STLN Oncology Institute, Inc.
Insider trading from SEC Form 4. Last filing Aug 24, 2026. Close $6.63 on Oct 9, 2026, +178% from the 52-week low and -6% from the high.
In brief
Oncology Institute, Inc. (STLN) has 101 SEC Form 4 filings on file from 16 insiders, the latest filed on Aug 24, 2026. In the last 90 days insiders made 2 open-market buys worth $173k and 2 open-market sells worth $2.1M, net -$1.9M.
32 open-market trades have been scored at STLN. The newest: Brad Hively (director) sold $1.9M of stock on Aug 21, 2026, filed Aug 24, 2026, scored 30 (weak), under a 10b5-1 plan. The largest of the 32 shown: M33 Growth I L.P. (director and 10% owner) sold $21M on Sep 4, 2025, scored 50 (moderate). 2 insiders sold within 14 days of each other around Jun 5, 2025.
14 Form 144 notices of planned sales are on file, the latest filed Aug 21, 2026.
Last 90 days
Net insider value
-$1.9M
more sold than bought
Buys
2
$173k by 1 insider
Sells
2
$2.1M by 2 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
STLNOct 9, 2026 · close 6.63
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Oncology Institute, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Brad Hively director sell | $1.9M 298,853 shares | -42% | +171% from low-3% from high | |
| 26Weak | Jorey Chernett owner buy | $78k 12,000 shares | +0% | +170% from low0% from high | |
| 27Weak | Jorey Chernett owner buy | $95k 18,000 shares | +0% | +128% from low-14% from high | |
| 0Weak | Yale Podnos Chief Medical Officer sell | $150k 23,452 shares | -8% | +163% from low0% from high | |
| 26Weak | Jorey Chernett owner buy | $88k 15,000 shares | +0% | +147% from low0% from high | |
| 16Weak | Jorey Chernett owner buy | $90k 18,000 shares | +0% | +145% from low-5% from high | |
| 6Weak | Yale Podnos Chief Medical Officer sell | $126k 23,451 shares | -8% | +147% from low0% from high | |
| 14Weak | Jorey Chernett owner buy | $57k 12,000 shares | +0% | +131% from low-1% from high | |
| 18Weak | Jorey Chernett owner buy | $157k 38,500 shares | +0% | +100% from low-14% from high | |
| 17Weak | Jorey Chernett owner buy | $123k 30,000 shares | +0% | +100% from low-14% from high | |
| 20Weak | Mohit Kaushal director sell | $335k 95,719 shares | -36% | +78% from low-29% from high | |
| 22Weak | Jorey Chernett owner buy | $62k 20,000 shares | +0% | +98% from low-35% from high | |
| 24Weak | Jorey Chernett owner buy | $81k 27,429 shares | +0% | +167% from low-38% from high | |
| 26Weak | Jorey Chernett owner buy | $158k 50,000 shares | +0% | +179% from low-35% from high | |
| 36Weak | Jorey Chernett owner buy | $389k 125,000 shares | +1% | +182% from low-34% from high | |
| 24Weak | Jorey Chernett owner buy | $84k 25,000 shares | +0% | +246% from low-30% from high | |
| 40Moderate | Jorey Chernett owner buy | $1.2M 398,985 shares | +4% | +337% from low-40% from high | |
| 22Weak | Robert Ross Carter Chief Financial Officer sell | $879 247 shares | -0% | +1153% from low-23% from high | |
| 22Weak | Brad Hively director sell | $50k 13,333 shares | -2% | +1927% from low-21% from high | |
| 32Weak | Mark L Pacala director sell | $200k 50,000 shares | -22% | +2756% from low-21% from high | |
| 50Moderate | M33 Growth I L.P. director, owner sell | $21M 6,700,000 shares | -48% | +2370% from low-24% from high | |
| 24Weak | Brad Hively director sell | $82k 20,221 shares | -3% | +2794% from low-11% from high | |
| 48Moderate | M33 Growth I L.P. director, owner sell | $2.3M 750,000 shares | -5% | +2014% from low-16% from high | |
| 53Moderate | Brad Hively director sell | $5.7M 1,976,137 shares | -77% | +2324% from low-3% from high | |
| 53Moderate | M33 Growth I L.P. director, owner sell | $5.4M 2,000,000 shares | -12% | +2006% from low-16% from high | |
| 39Weak | Brad Hively director buy | $47k 45,280 shares | +7% | +817% from low-4% from high | |
| 65Notable | Richard A Barasch director buy | $1.4M 1,358,448 shares | +326% | - | |
| 43Moderate | Robert Ross Carter Chief Financial Officer buy | $9,434 9,056 shares | +30% | +817% from low-4% from high | |
| 38Weak | Jeremy Castle Chief Operating Officer buy | $9,434 9,056 shares | +11% | +817% from low-4% from high | |
| 30Weak | Brad Hively director buy | $9,434 9,056 shares | +1% | +817% from low-4% from high | |
| 42Moderate | Karen Marie Johnson director buy | $38k 36,224 shares | +22% | +817% from low-4% from high | |
| 32Weak | Brad Hively director buy | $50k 300,000 shares | +82% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 21, 2026 | BRADFORD HIVELY Director | 298,853 0.29% of outstanding | $2.0M | Aug 21, 2026 | none |
| Jul 14, 2026 | YALE PODNOS Officer | 23,452 0.02% of outstanding | $147k | Jul 14, 2026 | $134k |
| Jun 8, 2026 | YALE PODNOS Officer | 23,451 0.02% of outstanding | $114k | Jun 8, 2026 | $70k |
| Apr 14, 2026 | MOHIT KAUSHAL Director | 95,719 0.10% of outstanding | $316k | Apr 14, 2026 | none |
| Dec 15, 2025 | BRADFORD DANIEL HIVELY Director | 13,333 0.01% of outstanding | $50k | Dec 15, 2025 | none |
| Nov 18, 2025 | MARK PACALA Director | 50,000 0.05% of outstanding | $200k | Nov 18, 2025 | none |
| Jun 5, 2025 | M33 Growth I L.P. 10% Stockholder | 1,122,793 1.26% of outstanding | $3.6M | Jun 5, 2025 | $5.5M |
| Jun 5, 2025 | TOI M, LLC 10% Stockholder | 127,207 0.14% of outstanding | $407k | Jun 5, 2025 | $623k |
| Jun 3, 2025 | BRADFORD DANIEL HIVELY Director | 1,936,537 2.17% of outstanding | $5.6M | Jun 3, 2025 | none |
| Jun 3, 2025 | BRADFORD DANIEL HIVELY Director | 39,600 0.04% of outstanding | $114k | Jun 3, 2025 | none |
| May 20, 2025 | M33 Growth I L.P. 10% Stockholder | 1,796,468 2.01% of outstanding | $5.5M | May 20, 2025 | none |
| May 20, 2025 | TOI M, LLC 10% Stockholder | 203,532 0.23% of outstanding | $623k | May 20, 2025 | none |
| Nov 17, 2023 | Hively Brad Director | 25,000 0.03% of outstanding | $56k | Nov 17, 2023 | $183k |
| Nov 13, 2023 | Hively Brad Director | 47,000 0.06% of outstanding | $119k | Nov 13, 2023 | none |
Transactions
The newest 50 of 153 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Brad Hively director | SOpen-market sale Common Stock10b5-1 | -298,853 | $6.51 | $1.9M | 411,976 | Aug 24, 2026 |
| Aug 14, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +12,000 | $6.54 | $78k | 10,660,858 | Aug 17, 2026 |
| Aug 13, 2026 | Jorey Chernett owner | SOpen-market sale Call Option (STLN 19FEB27 $9C)derivative | -100 | $6.24 | $624 | 0 | Aug 17, 2026 |
| Jul 27, 2026 | Mark Stolper director | AGrant or award Common Stock | +31,124 | $0.00 | $0 | 56,957 | Jul 29, 2026 |
| Jul 27, 2026 | Brad Hively director | AGrant or award Common Stock | +27,108 | $0.00 | $0 | 710,829 | Jul 29, 2026 |
| Jul 27, 2026 | Mark L Pacala director | AGrant or award Common Stock | +30,120 | $0.00 | $0 | 286,881 | Jul 29, 2026 |
| Jul 27, 2026 | Karen Marie Johnson director | AGrant or award Common Stock | +31,124 | $0.00 | $0 | 319,410 | Jul 29, 2026 |
| Jul 27, 2026 | Mohit Kaushal director | AGrant or award Common Stock | +33,133 | $0.00 | $0 | 205,716 | Jul 29, 2026 |
| Jul 27, 2026 | Anne McGeorge director | AGrant or award Common Stock | +41,165 | $0.00 | $0 | 332,535 | Jul 29, 2026 |
| Jul 27, 2026 | Kimberly Jo Tzoumakas director | AGrant or award Common Stock | +29,116 | $0.00 | $0 | 46,301 | Jul 29, 2026 |
| Jul 21, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +18,000 | $5.27 | $95k | 10,648,858 | Jul 22, 2026 |
| Jul 14, 2026 | Yale Podnos Chief Medical Officer | MOption exercise Common Stock10b5-1 | +17,974 | $1.87 | $34k | 277,501 | Jul 16, 2026 |
| Jul 14, 2026 | Yale Podnos Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -17,974 | $6.43 | $116k | 259,527 | Jul 16, 2026 |
| Jul 14, 2026 | Yale Podnos Chief Medical Officer | MOption exercise Common Stock10b5-1 | +5,478 | $2.00 | $11k | 265,005 | Jul 16, 2026 |
| Jul 14, 2026 | Yale Podnos Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,478 | $6.35 | $35k | 259,527 | Jul 16, 2026 |
| Jul 14, 2026 | Yale Podnos Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +17,974 | $1.87 | $34k | 0 | Jul 16, 2026 |
| Jul 14, 2026 | Yale Podnos Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +5,478 | $2.00 | $11k | 0 | Jul 16, 2026 |
| Jul 10, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +15,000 | $5.85 | $88k | 10,630,858 | Jul 13, 2026 |
| Jul 7, 2026 | Mark Stolper director | AGrant or award Common Stock | +25,833 | $0.00 | $0 | 25,833 | Jul 9, 2026 |
| Jul 7, 2026 | Kimberly Jo Tzoumakas director | AGrant or award Common Stock | +17,185 | $0.00 | $0 | 17,185 | Jul 9, 2026 |
| Jun 23, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +18,000 | $5.02 | $90k | 10,615,858 | Jun 24, 2026 |
| Jun 8, 2026 | Yale Podnos Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -23,451 | $5.38 | $126k | 259,527 | Jun 9, 2026 |
| Jun 4, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +12,000 | $4.75 | $57k | 10,579,858 | Jun 5, 2026 |
| May 21, 2026 | Robert Ross Carter Chief Financial Officer | JOther Common Stock | -1,604 | $4.47 | $7,170 | 414,801 | May 22, 2026 |
| May 21, 2026 | Daniel Virnich Chief Executive Officer | JOther Common Stock | -23,058 | $4.47 | $103k | 2,337,166 | May 22, 2026 |
| May 21, 2026 | Yale Podnos Chief Medical Officer | JOther Common Stock | -1,805 | $4.47 | $8,068 | 282,978 | May 22, 2026 |
| May 19, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +5,000 | $4.05 | $20k | 10,534,358 | May 21, 2026 |
| May 20, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +33,500 | $4.07 | $136k | 10,567,858 | May 21, 2026 |
| May 19, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +30,000 | $4.09 | $123k | 10,529,358 | May 20, 2026 |
| Apr 14, 2026 | Mohit Kaushal director | SOpen-market sale Common Stock10b5-1 | -57,286 | $3.50 | $201k | 211,016 | Apr 16, 2026 |
| Apr 16, 2026 | Mohit Kaushal director | SOpen-market sale Common Stock10b5-1 | -38,433 | $3.50 | $135k | 172,583 | Apr 16, 2026 |
| Apr 9, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +20,000 | $3.10 | $62k | 10,499,358 | Apr 13, 2026 |
| Mar 27, 2026 | Robert Ross Carter Chief Financial Officer | AGrant or award Common Stock | -202,914 | $0.00 | $0 | 436,725 | Apr 1, 2026 |
| Mar 27, 2026 | Kristin England Chief Administrative Officer | AGrant or award Common Stock | +55,743 | $0.00 | $0 | 153,780 | Apr 1, 2026 |
| Mar 27, 2026 | Jeffrey Langsam Chief Clinical Officer | AGrant or award Common Stock | +70,270 | $0.00 | $0 | 127,650 | Apr 1, 2026 |
| Mar 27, 2026 | Daniel Virnich Chief Executive Officer | AGrant or award Common Stock | -670,608 | $0.00 | $0 | 2,458,758 | Apr 1, 2026 |
| Mar 27, 2026 | Yale Podnos Chief Medical Officer | AGrant or award Common Stock | +66,446 | $0.00 | $0 | 300,956 | Apr 1, 2026 |
| Mar 27, 2026 | Robert Ross Carter Chief Financial Officer | JOther Common Stock | -20,320 | $3.07 | $62k | 416,405 | Apr 1, 2026 |
| Mar 27, 2026 | Daniel Virnich Chief Executive Officer | JOther Common Stock | -98,534 | $3.07 | $302k | 2,360,224 | Apr 1, 2026 |
| Mar 27, 2026 | Yale Podnos Chief Medical Officer | JOther Common Stock | -16,173 | $3.07 | $50k | 284,783 | Apr 1, 2026 |
| Mar 27, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +27,429 | $2.96 | $81k | 10,479,358 | Mar 30, 2026 |
| Mar 26, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +50,000 | $3.15 | $158k | 10,451,929 | Mar 27, 2026 |
| Mar 24, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +125,000 | $3.11 | $389k | 10,401,929 | Mar 25, 2026 |
| Mar 20, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +25,000 | $3.35 | $84k | 10,276,929 | Mar 23, 2026 |
| Mar 17, 2026 | Robert Ross Carter Chief Financial Officer | JOther Common Stock | -1,314 | $3.59 | $4,717 | 233,811 | Mar 18, 2026 |
| Mar 17, 2026 | Yale Podnos Chief Medical Officer | JOther Common Stock | -3,420 | $3.59 | $12k | 234,510 | Mar 18, 2026 |
| Mar 17, 2026 | Daniel Virnich Chief Executive Officer | JOther Common Stock | -11,834 | $3.59 | $42k | 1,788,150 | Mar 18, 2026 |
| Mar 13, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +263,000 | $2.92 | $768k | 10,115,944 | Mar 17, 2026 |
| Mar 16, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +60,985 | $3.29 | $201k | 10,176,929 | Mar 17, 2026 |
| Mar 17, 2026 | Jorey Chernett owner | POpen-market purchase Common Stock | +75,000 | $3.42 | $257k | 10,251,929 | Mar 17, 2026 |
50 of 153 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Richard A Baraschdirector, ceo, officer
- Robert Ross CarterChief Financial Officer
- Jeremy CastleChief Operating Officer
- Jorey Chernettowner
- Kristin EnglandChief Administrative Officer
- Brad Hivelydirector
- Karen Marie Johnsondirector
- Mohit Kaushaldirector
- Jeffrey LangsamChief Clinical Officer
- M33 Growth I L.P.director, owner
- Anne McGeorgedirector
- Mark L Pacaladirector
- Yale PodnosChief Medical Officer
- Mark Stolpercfo, officer, director
- Kimberly Jo Tzoumakasdirector
- Daniel VirnichChief Executive Officer
Questions about STLN
Answered from the filings on this page, as of the latest one.
Are insiders buying STLN?
As of Aug 24, 2026, SEC Form 4 filings show 2 open-market buys worth $173k by 1 insider and 2 open-market sells worth $2.1M by 2 insiders at Oncology Institute, Inc. in the last 90 days, net -$1.9M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade STLN on the open market?
Brad Hively (director) sold $1.9M of STLN on Aug 21, 2026 and filed the Form 4 on Aug 24, 2026. InsiderTell scored 30 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Oncology Institute, Inc.?
16 people have filed a Form 4 at Oncology Institute, Inc., among them Richard A Barasch (director and CEO), Robert Ross Carter (Chief Financial Officer), Jeremy Castle (Chief Operating Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.